Qiagen decides against sale following review

Dec 24 (Reuters) - Genetic testing firm Qiagen NV said on Tuesday it has concluded a review of potential alternatives, including a sale of the company, and determined that continuing to be a stand-alone business is its best option.

Qiagen said it got several indications of interest for an acquisition, but has now terminated all discussions. (https://bwnews.pr/2ZrrG5d) (Reporting by Roshan Abraham in Bengaluru; Editing by Shounak Dasgupta)

Related Tags